[粒细胞集落刺激因子（惠尔血）对免疫麻痹脓毒症患者的免疫刺激作用]

[Immune stimulation with G-CSF (Neupogen) in septic patients with immune paralysis].

作者信息

Agnes A, Zippel K, Zuckermann H, Döcke W D, Volk H D, Müller J M

机构信息

Klinik für Chirurgie, Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin.

出版信息

Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1077-9.

PMID:9931795

Abstract

Ten patients with sepsis (HLA-DR+ monocytes < 30%) were treated with G-CSF (300 mg Filgrastin, Neupogen 30, Amgen). All patients showed a rise in HLA-DR+ monocytes during therapy. In six patients the high level of HLA-DR+ monocytes persisted after therapy; these patients survived. In the other four patients the number of HLA-DR+ monocytes declined after application of G-CSF, and the patients died of multiorgan failure. Some patients with sepsis might profit from immunestimulating therapy with G-CSF, but further studies are needed to prove whether or not this is true.

摘要

10例脓毒症患者（人类白细胞抗原-DR+单核细胞<30%）接受了粒细胞集落刺激因子治疗（300mg非格司亭，优保津30，安进公司）。所有患者在治疗期间人类白细胞抗原-DR+单核细胞均出现升高。6例患者在治疗后人类白细胞抗原-DR+单核细胞维持在高水平；这些患者存活。另外4例患者在应用粒细胞集落刺激因子后人类白细胞抗原-DR+单核细胞数量下降，患者死于多器官功能衰竭。一些脓毒症患者可能从粒细胞集落刺激因子免疫刺激治疗中获益，但需要进一步研究来证实这是否属实。